Anti-tumor immunity via IL-12 delivery in the tumor microenvironment

Active Grant Awarded

Award ID
RCA308075UJFL45
Recipient
Awarding agency
Obligated
$0

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 1% complete
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Description

Abstract
Poor tumor infiltration, the immunosuppressive tumor microenvironment, and lack of T cell antigen exposure are believed to limit the success of adoptive T cell therapy (act) in solid tumors, but combining cytokine therapy with act may dramatically enhance its impact. While a number of cytokines have shown promise, most traditionally formulated systemic cytokine injections have failed in the clinic. These failures likely rest, in part, on the inability to achieve therapeutic concentrations within tumors, and toxicity related to the rapid systemic increases of a variety of pro-inflammatory cytokines (cytokine storm) with this delivery approach. We have developed a microparticle delivery system based on mesoporous silica rods (MSRS) that provides a depot for sustained IL-12 release (MSR/IL-12) following intratumoral injection into solid tumors. MSRS have a high nanopore volume and resulting large surface area to allow for ready adsorption and release of large quantities of payload. Synthetic amorphous silica is degradable, and known to have good biocompatibility, supporting its development as a versatile platform for clinical applications. IL-12 is a potent, pro-inflammatory cytokine that has demonstrated remarkable antitumor effects against solid tumors in a variety of preclinical studies, but systemic administrations have been toxic and demonstrated little efficacy. Here we will explore the utility of MSR/IL-12 delivery both alone for solid tumors, as well as its ability to improve the efficacy of car-T therapy against solid tumors. This project is based on the hypothesis that sustained presentation of IL-12 from MSR in the tumor microenvironment will activate both host immune cells and transferred cytotoxic T cells, leading to solid tumor debulking, and generation of systemic anti-tumor immunity. This hypothesis will be explored with the following specific aims: (1) alter MSR surface chemistry to modulate MSR IL-12 release duration from days to weeks, and determine the relation between IL-12 release duration/dose and therapeutic efficacy in preclinical models of solid tumors. (2) establish the ability of MSR/IL-12 delivery to enhance the therapeutic efficacy of act directed against solid tumors. (3) analyze the mechanism(S) underlying the MSR/IL-12 therapeutic effects. (4) demonstrate the reproducibility of the MSR/IL-12 manufacturing process. The MSR delivery system provides a new approach to intratumoral delivery of cytokines, both with and in the absence of act, and is anticipated to enhance the function of both adoptively transferred and host immune cells. We anticipate this will allow the efficacy of act in the context of solid tumors to be significantly enhanced, while minimizing side-effects of systemic cytokine therapy. This project will be pursued via a collaboration of the mooney laboratory at harvard, where the MSR delivery system was initiated, and attivare, that is developing the MSR delivery system for clinical translation. The data arising from this project will, in addition to being published, be utilized by attivare in its IND filing to the FDA.

Quick answers

Who received award RCA308075UJFL45?

RCA308075UJFL45 was awarded to President And Fellows Of Harvard College by National Cancer Institute (National Institutes of Health) on October 28, 2026.

How much is award RCA308075UJFL45 worth?

$0 has been obligated on RCA308075UJFL45.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award